Angiosonics plans ultrasound clot-buster launch
This article was originally published in Clinica
Angiosonics plans to launch its ultrasound clot-buster outside the US this summer. The US company has asked the FDA for permission to begin trials of the Acolysis system, which uses a high frequency ultrasound catheter to break down blood clots in coronary arteries. Angiosonics plans to pursue peripheral artery applications next year. Clinical trials have already begun in Tel Aviv, Israel, where 15 heart attack patients have been treated. Angiosonics plans to pursue peripheral artery applications next year.
You may also be interested in...
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.